Results 1 to 10 of about 3,000,675 (307)

Phase 3 Trial of 177Lu-Dotatate for Midgut Neuroendocrine Tumors [PDF]

New England Journal of Medicine, 2017
Background Patients with advanced midgut neuroendocrine tumors who have had disease progression during first-line somatostatin analogue therapy have limited therapeutic options.
Al‐nahhas, A, Ansquer, C, Anthony, L, Azevedo, I, Baudin, E, Baum, Rp, Baum, Rp, Benson, A, Benson, Ab, Berlin, J, Berlin, J, Bodei, L, Brianzoni, E, Bushnell, D, Bushnell, D, Caplin, M, Caplin, M, Chasen, B, Chiara Grana, M, Courbon, F, DELLE FAVE, Gianfranco, Delpassand, E, Delpassand, E, El Haddad, G, Erion, Jl, Freemantle, N, Garbus, S, Giammarile, F, Grande, E, Grande, E, Grossman, A, Hendifar, A, Hendifar, A, Hobday, T, Hobday, T, Jacene, H, Krenning, E, Kulkarni, Hr, Kulke, M, Kulke, Mh, Kunz, Pl, Kvols, L, Kwekkeboom, D, Lebtahi, R, Lopera Sierra, M, Manoharan, P, Mariani, G, Metz, D, Mittra, E, Mittra, E, Mora, J, Mora, J, Morse, M, O'Dorisio, Tm, Pavel, M, Pavel, M, Reed, N, Reed, N, Rindi, G, Ruszniewski, P, Ruszniewski, P, Santoro, P, Scheidhauer, K, Schipper, M, Seregni, E, Seregni, E, Severi, S, Srirajaskanthan, R, Srirajaskanthan, R, Strosberg, J, Strosberg, J, Sundin, A, Taieb, D, Thevenet, T, Van Cutsem, E, Van Cutsem, E, Weber, M, Wolin, E, Wolin, E, Yao, J, Yao, J., Öberg, K, Öberg, K   +82 more
core   +2 more sources

Somatostatin Analogues in the Treatment of Neuroendocrine Tumors: Past, Present and Future [PDF]

International Journal of Molecular Sciences, 2019
In recent decades, the incidence of neuroendocrine tumors (NETs) has steadily increased. Due to the slow-growing nature of these tumors and the lack of early symptoms, most cases are diagnosed at advanced stages, when curative treatment options are no ...
Amthauer, Holger, Jann, Henning, Kayser, Antonin, Roderburg, Christoph, Stueven, Anna Kathrin, Tacke, Frank, Wetz, Christoph, Wiedenmann, Bertram, Wree, Alexander   +8 more
core   +2 more sources

Pituitary neuroendocrine tumors: a model for neuroendocrine tumor classification

Modern Pathology, 2021
The classification of adenohypophysial neoplasms as "pituitary neuroendocrine tumors" (PitNETs) was proposed in 2017 to reflect their characteristics as epithelial neuroendocrine neoplasms with a spectrum of clinical behaviors ranging from small indolent lesions to large, locally invasive, unresectable tumors.
Sylvia L. Asa, Ozgur Mete, Michael D. Cusimano, Ian E. McCutcheon, Arie Perry, Shozo Yamada, Hiroshi Nishioka, Olivera Casar-Borota, Silvia Uccella, Stefano La Rosa, Ashley B. Grossman, Shereen Ezzat, null International Pituitary Pathology, Sofia Asioli, Süheyla Uyar Bozkurt, Nil Comunoglu, Giulia Cossu, Peter Earls, Nuperi Gazioglu, Richard A. Hickman, Hidetoshi Ikeda, Emilija Manojlovic-Gacic, Mahmoud Messerer, Buge Öz, Sara Pakbaz, Federico Roncaroli, Wolfgang Saeger, John Turchini, Sema Yarman   +28 more
openaire   +4 more sources

A Phase II Basket Trial of Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors (DART SWOG 1609) in Patients with Nonpancreatic Neuroendocrine Tumors. [PDF]

Clinical Cancer Research, 2020
PurposeImmune checkpoint blockade has improved outcomes across tumor types; little is known about the efficacy of these agents in rare tumors. We report the results of the (nonpancreatic) neuroendocrine neoplasm cohort of SWOG S1609 dual anti-CTLA-4 and ...
Baghdadi, Tareq Al, Blanke, Charles D, Chae, Young Kwang, Chen, Helen X, Fontaine, Annette, Gatalica, Zoran, Giles, Francis J, Hansel, Donna E, Hayward, Jourdain, Kasi, Anup, Korn, W Michael, Kurzrock, Razelle, Matrana, Marc, Mayerson, Edward, McLeod, Christine, Othus, Megan, Patel, Sandip P, Plets, Melissa, Ryan, Christopher W, Shah, Manisha H, Sharon, Elad, Singh, Preet Paul   +21 more
core   +2 more sources

miR375-3p Distinguishes Low-Grade Neuroendocrine From Non-neuroendocrine Lung Tumors in FFPE Samples [PDF]

Frontiers in Molecular Biosciences, 2020
Lung cancer is still one of the leading cause of death worldwide. The clinical variability of lung cancer is high and drives treatment decision. In this context, correct discrimination of pulmonary neuroendocrine tumors is still of critical relevance ...
Simone Detassis, Valerio del Vescovo, Margherita Grasso, Stefania Masella, Chiara Cantaloni, Luca Cima, Alberto Cavazza, Paolo Graziano, Giulio Rossi, Mattia Barbareschi, Leonardo Ricci, Leonardo Ricci, Michela Alessandra Denti   +12 more
doaj   +3 more sources

Neuroendocrine tumors involving the gastroenteropancreatic tract: a clinicopathological evaluation of 773 cases [PDF]

Clinics, 2011
OBJECTIVE: Description of some of the clinical pathological characteristics of neuroendocrine tumors of the gastroenteropancreatic tract in Brazilian patients.
Bruna Estrozi, Carlos E. Bacchi
doaj   +5 more sources

Neuroendocrine tumors in the brain [PDF]

Annals of Oncology, 2001
Somatostatin and other neuropeptides are expressed in tumors originating from neuronal precursors and paraganglia, namely medulloblastoma, central Primitive Neuro-Ectodermal Tumors (cPNETs), neurocytoma, gangliocytoma. olfactory neuroblastoma, paraganglioma.
Paola Cavalla, D. Schiffer
openalex   +3 more sources

Expression of a neuroendocrine gene signature in gastric tumor cells from CEA 424-SV40 large T antigen-transgenic mice depends on SV40 large T antigen. [PDF]

PLoS ONE, 2012
BackgroundA large fraction of murine tumors induced by transgenic expression of SV40 large T antigen (SV40 TAg) exhibits a neuroendocrine phenotype. It is unclear whether SV40 TAg induces the neuroendocrine phenotype by preferential transformation of ...
Fritz Ihler, Elena Viviana Vetter, Jie Pan, Robert Kammerer, Svenja Debey-Pascher, Joachim L Schultze, Wolfgang Zimmermann, Georg Enders   +7 more
doaj   +7 more sources

Pancreatic neuroendocrine tumors

Revista Española de Enfermedades Digestivas, 2017
Endocrine or pancreatic neuroendocrine tumors (PNET) were first cited in the 1950s; they may be sporadic or associated with hereditary syndromes, benign or malignant, functioning or non-functioning. Nowadays, NF-PNETs are the most frequent and their prevalence ranges from 50% to 91%. In our current series (including 70 cases, 33% malignant, 52 operated)
Varas-Lorenzo, Modesto J., Cugat-Andorra, Esteban, Capdevila-Castillón, Jaume   +2 more
openaire   +7 more sources

Neuroendocrine tumors of the prostate [PDF]

Modern Pathology, 2018
Neuroendocrine (NE) differentiation in tumors of the prostate or in the setting of prostate cancer (PCa) is rare. A survey of these lesions is presented, including usual PCa with focal NE marker-positive cells, Paneth cell-like change, prostatic 'carcinoid', high-grade NE carcinoma, as well as other tumors that do not fit neatly into these categories ...
S. Fine
openaire   +4 more sources